|
TMEM168 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.24340015850555E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.11820000428631E-08 |
| Normal-vs-Stage2 |
6.082100E-03 |
| Normal-vs-Stage3 |
3.37439964859243E-10 |
| Normal-vs-Stage4 |
3.22875060021488E-12 |
| Stage1-vs-Stage2 |
9.395600E-02 |
| Stage1-vs-Stage3 |
1.706330E-02 |
| Stage1-vs-Stage4 |
2.847100E-04 |
| Stage2-vs-Stage3 |
3.675300E-03 |
| Stage2-vs-Stage4 |
2.449200E-04 |
| Stage3-vs-Stage4 |
2.248000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.00379712822496E-11 |
| Normal-vs-AfricanAmerican |
3.93269999999779E-05 |
| Normal-vs-Asian |
1.77309999999098E-05 |
| Caucasian-vs-AfricanAmerican |
9.451800E-01 |
| Caucasian-vs-Asian |
1.829970E-01 |
| AfricanAmerican-vs-Asian |
3.316200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.92340002100633E-09 |
| Normal-vs-Female |
2.90809998304553E-09 |
| Male-vs-Female |
6.870200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63309999967609E-08 |
| Normal-vs-Age(41-60Yrs) |
1.80490000722955E-09 |
| Normal-vs-Age(61-80Yrs) |
4.87919999958564E-07 |
| Normal-vs-Age(81-100Yrs) |
5.143700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.497200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.201200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.791600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.723400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.264600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.573400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.8378699999988E-05 |
| Classical-VS-Follicular |
1.338270E-03 |
| Classical-VS-Other |
5.217400E-01 |
| Classical-VS-Normal |
1.69199987354318E-10 |
| Tall-VS-Follicular |
6.8676000442025E-09 |
| Tall-VS-Other |
1.437170E-01 |
| Tall-VS-Normal |
1.59539048638635E-13 |
| Follicular-VS-Other |
2.028300E-02 |
| Follicular-VS-Normal |
2.593700E-02 |
| Other-VS-Normal |
2.635100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.52789999985359E-07 |
| Normal-vs-N1 |
3.69779995512687E-09 |
| N0-vs-N1 |
1.068610E-01 |
|
|
